First data for Spark's hemophilia B gene therapy

Spark Therapeutics Inc. (NASDAQ:ONCE) gained $5.94 (14%) to $47.17 on Thursday after it and partner Pfizer Inc. (NYSE:PFE) said the first three hemophilia B patients enrolled in a Phase I/II study of SPK-9001 ( SPK-FIX) had

Read the full 363 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE